- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The National Security and Investment Act 2021 (Notifiable Acquisition) (Specification of Qualifying Entities) Regulations 2021, SCHEDULE 16.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 2
1. In this Schedule—
“basic scientific research” means experimental or theoretical work undertaken principally to acquire new knowledge of the fundamental principles of phenomena or observable facts and not primarily directed towards a specific practicable aim or objective;
“medicine” means—
any substance or combination of substances presented as having properties of preventing or treating disease in human beings or animals;
any substance or combination of substances that may be used by or administered to human beings or animals with a view to—
restoring, correcting or modifying a physiological function by asserting a pharmacological, immunological or metabolic action;
making a medical diagnosis;
“services” means routine synthetic biology processes that are outsourced to specialist providers for completion before being re-integrated into the original work stream to assemble into an experiment or goods, including making a specific strand of DNA or running a proprietary algorithm on a dataset.
Commencement Information
I1Sch. 16 para. 1 in force at 4.1.2022, see reg. 1(2)
2. Subject to the exceptions referred to in paragraphs 5 and 6, a qualifying entity carrying on activities that consist of or include any of the following—
(a)carrying on basic scientific research into synthetic biology;
(b)the development of synthetic biology;
(c)the production of goods using synthetic biology;
(d)the formulation of synthetic biology to enable the degradation of materials;
(e)the provision of services that enable the activities in paragraphs (a) to (d).
Commencement Information
I2Sch. 16 para. 2 in force at 4.1.2022, see reg. 1(2)
3. In this Schedule, “synthetic biology” means the process of applying engineering principles to biology to design, redesign or make biological components or systems that do not exist in the natural world.
Commencement Information
I3Sch. 16 para. 3 in force at 4.1.2022, see reg. 1(2)
4. Synthetic biology includes but is not limited to—
(a)the design and engineering of biological-based parts of—
(i)enzymes;
(ii)genetic circuits and cells;
(iii)novel devices and systems;
(b)redesigning existing natural biological systems;
(c)using microbes to template materials;
(d)cell-free systems;
(e)gene editing and gene therapy;
(f)the use of DNA for data storage, encryption and bio-enabled computing.
Commencement Information
I4Sch. 16 para. 4 in force at 4.1.2022, see reg. 1(2)
5. Exceptions to the activities described in paragraph 2 are—
(a)general services or servicing not related to core synthetic biology, where “core” means those activities without which experiments cannot be conducted, such as DNA synthesis or cloning;
(b)the use of microorganisms to remove harmful contaminants, pollutants or toxins from the environment (known as bioremediation), including bio-based reagents that allow for testing for contaminants;
(c)any approach used to gather clinical information for the purpose of making a clinical decision or making a diagnosis (known as diagnostics) but not the storage or ownership of sensitive human genetic information that enables the identification of an individual;
(d)industrial biotechnology research, development or production using enzymes or organisms that have not been modified through the application of synthetic biology;
(e)the production of substances ordinarily consumed as food or used as feed, including any ingredient or component of such substances;
(f)gene therapy, where it is used solely for the purpose of replacing missing or defective genes to restore phenotypes to achieve a therapeutic effect;
(g)cell therapy, where cells are modified by genetic engineering and then introduced into a patient to treat disease.
Commencement Information
I5Sch. 16 para. 5 in force at 4.1.2022, see reg. 1(2)
6.—(1) Exceptions to the activities described in paragraph 2 are the ownership, ownership of intellectual property or development of the matters set out in sub-paragraph (2) that employ synthetic biology at any stage of the development or production, unless the circumstances set out in sub-paragraph (3) apply.
(2) The matters referred to in sub-paragraph (1) are—
(a)human or veterinary medicines;
(b)immunomodulatory approaches.
(3) The circumstances referred to in sub-paragraph (1) are where the matter described in sub-paragraph (2)—
(a)has a synthetic biology technology that could be employed or modified to produce, deliver or produce and deliver—
(i)toxic chemicals to achieve an incapacitating or lethal effect on humans or animals;
(ii)materials restricted under Schedule 5 to the Anti-terrorism, Crime and Security Act 2001(1); or
(b)uses substances or pathogens set out in Schedule 5 to the Anti-terrorism, Crime and Security Act 2001.
Commencement Information
I6Sch. 16 para. 6 in force at 4.1.2022, see reg. 1(2)
Schedule 5 was amended by S.I. 2007/929 and 2012/1466.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: